| Dr Thomas J Mackarevich, PHD, LCSW, LCADC | |
|
15 Grand Ave, Toms River, NJ 08753-7503 | |
| (732) 240-9352 | |
| (732) 240-9352 |
| Full Name | Dr Thomas J Mackarevich |
|---|---|
| Gender | Male |
| Speciality | Social Worker - Clinical |
| Location | 15 Grand Ave, Toms River, New Jersey |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043400252 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YA0400X | Counselor - Addiction (substance Use Disorder) | 37LC00102900 (New Jersey) | Secondary |
| 1041C0700X | Social Worker - Clinical | 44SC04807300 (New Jersey) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Thomas J Mackarevich, PHD, LCSW, LCADC 15 Grand Ave, Toms River, NJ 08753-7503 Ph: (732) 240-9352 | Dr Thomas J Mackarevich, PHD, LCSW, LCADC 15 Grand Ave, Toms River, NJ 08753-7503 Ph: (732) 240-9352 |
News Archive
BioTrends Research Group, Inc. recently published its TreatmentTrends: Renal Anemia in China report. This report is based on survey results from 150 nephrologists in clinical practice in China and qualitative interviews conducted with ten thought leaders in nephrology. The report examines the demographics of nephrology practice in China and focuses specifically on the management of renal anemia amongst dialysis and later stage chronic kidney disease patients.
Antares Pharma, Inc. (NYSE Amex: AIS) today announced that its partner Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) has launched its new Tjet™ needle-free injector system for the administration of human growth hormone (hGH). The Tjet™ device will be available exclusively in combination with the Teva hGH product Tev-Tropin® [somatropin (rDNA) for injection].
Taking aim at the alarming slowdown in the development of new and lifesaving drugs, Harvard Medical School is launching an Initiative in Systems Pharmacology, a comprehensive strategy to transform drug discovery by convening biologists, chemists, pharmacologists, physicists, computer scientists and clinicians to explore together how drugs work in complex systems.
BIOCIUS Life Sciences Inc., developers of the RapidFire® high-throughput mass spectrometry system, today announced execution of a lease agreement for a new Corporate Headquarters in Wakefield, MA. The new facility located at 11 Audubon Road doubles the company's capacity and is a result of the increase in demand for RapidFire products and services.
› Verified 3 days ago